The Bristol based investigation software provider raised the capital from Frog Capital, angels and employees to fund product development and expansion.
"This funding is the latest step in our journey of supporting investigations and intelligence teams across the globe. Our mission to protect society from harm goes beyond developing intelligence and investigation software. We are building a networked community of investigation professionals across sectors worldwide to explore common challenges and share best practices."
The Series A round was led by 20VC and Chalfen Ventures to accelerate product development in clean energy markets.
"Energy and commodities account for around $5trillion worth of world trade, and price benchmarks are used in the majority of those contracts. Historically, these benchmarks have been created manually by journalists in traditional media organisations. The industry has found this inconsistent and expensive – often being forced to pay tens of millions of dollars for this data. This is exactly what GX is hereto disrupt! We’re bringing technology to produce better benchmarks, that objectively price the world’s trade. We are excited to work with 20VC alongside Chalfen Ventures to accelerate our expansion into the energy transition as these markets mature into tradable commodities."
ETFS Capital led the extension round, which will support the wealthtech provider's growth into European markets.
"We are pleased to provide further funding to WealthKernel. Having seen the business grow from strength to strength since we first invested in 2018, we look forward to supporting Karan and team as they continue this expansion into Europe. The demand for innovation in the wealth and asset management industry has never been higher, which WealthKernel is perfectly placed to deliver."
The financing round was led by Molten Ventures with backing from LifeX Ventures and private individuals.
"With our technology, we’re building the world’s largest immune data assets across health and disease, which allows us to perform analyses with a level of depth and granularity that was previously unthinkable. This systems-level approach to understanding immune function enables us to look at the bigger picture rather than just focusing on individual disease-associated parameters. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run."
— Adam Laing, President and Chief Scientific Officer
The Series A round was led by AlbionVC with backing from Dowgate Capital and private investors.
"We're building a category-defining business that redefines the way humans interact with technology and that makes advanced and Generative AI realizable for enterprises. Businesses are keen to take advantage of the technology they see manifested in applications like ChatGPT, but they're struggling to figure out how to make that a reality in a business context without exposing themselves to risks. We can offer them the security, granular control, explainability and safety which is essential for all businesses, but particularly those operating in regulated sectors like insurance, healthcare, financial services and utilities."
